304 related articles for article (PubMed ID: 28877978)
21. Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis.
Goyal G; Abeykoon JP; Hu M; Young JR; Shah MV; Bennani NN; Call TG; Hook CC; Pardanani A; Inwards DJ; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Davidge-Pitts CJ; Ravindran A; Rech KL; Go RS;
Am J Hematol; 2021 May; 96(5):E146-E150. PubMed ID: 33539584
[No Abstract] [Full Text] [Related]
22. Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis.
Dimmler A; Geddert H; Werner M; Faller G
Virchows Arch; 2017 Apr; 470(4):429-435. PubMed ID: 28220299
[TBL] [Abstract][Full Text] [Related]
23. Bronchoalveolar lavage for the diagnosis of Pulmonary Langerhans cell histiocytosis.
Lommatzsch M; Bratke K; Stoll P; Mülleneisen N; Prall F; Bier A; Virchow JC
Respir Med; 2016 Oct; 119():168-174. PubMed ID: 27692140
[TBL] [Abstract][Full Text] [Related]
24. [Adult pulmonary Langerhans' cell histiocytosis: approach to the reality of the Spanish population].
Castillo D; Martin-Arroyo I; Moreno A; Balcells E; Villar A; Vicens-Zygmunt V; Vendrell M; Belda S; Portillo K; Kettou D; Aparicio F; Molina-Molina M;
Med Clin (Barc); 2014 Nov; 143(10):433-9. PubMed ID: 24726261
[TBL] [Abstract][Full Text] [Related]
25. [An overview of histiocytosis].
Tojo A
Rinsho Ketsueki; 2022; 63(5):363-367. PubMed ID: 35662158
[TBL] [Abstract][Full Text] [Related]
26. Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.
Héritier S; Jehanne M; Leverger G; Emile JF; Alvarez JC; Haroche J; Donadieu J
JAMA Oncol; 2015 Sep; 1(6):836-8. PubMed ID: 26180941
[No Abstract] [Full Text] [Related]
27. Association between clinicopathologic characteristics and BRAF
Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
[TBL] [Abstract][Full Text] [Related]
28. Lung Transplant in a Patient With Multifocal Langerhans Cell Histiocytosis After Chemotherapy With Cladribine: A Case Report.
Abba ME; Żegleń S; Łącka M; Maruszewski M; Kowalski J; Stachowicz-Chojnacka K; Wojarski J; Ulatowski N; Karolak W
Transplant Proc; 2022 May; 54(4):1177-1179. PubMed ID: 35410720
[TBL] [Abstract][Full Text] [Related]
29. Assessment of BRAF
Pierry C; Caumont C; Blanchard E; Brochet C; Dournes G; Gros A; Bandres T; Verdon S; Marty M; Bégueret H; Merlio JP
Virchows Arch; 2018 Feb; 472(2):247-258. PubMed ID: 28711990
[TBL] [Abstract][Full Text] [Related]
30. Clinical analysis for 15 patients with pulmonary Langerhans cell histiocytosis and literature review.
Zhang L; Ouyang R
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Mar; 47(3):334-343. PubMed ID: 35545326
[TBL] [Abstract][Full Text] [Related]
31. Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review.
Elia D; Torre O; Cassandro R; Caminati A; Harari S
Eur J Intern Med; 2015 Jun; 26(5):351-6. PubMed ID: 25899682
[TBL] [Abstract][Full Text] [Related]
32. Advances in our understanding of genetic markers and targeted therapies for pediatric LCH.
Bahabri A; Abla O
Expert Rev Hematol; 2024 Jun; 17(6):223-231. PubMed ID: 38721670
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary Langerhans Cell Histiocytosis-associated Pulmonary Hypertension Showing a Drastic Improvement Following Smoking Cessation.
Kinoshita Y; Watanabe K; Sakamoto A; Hidaka K
Intern Med; 2016; 55(5):491-5. PubMed ID: 26935369
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes and survival following lung transplantation in patients with pulmonary Langerhans cell histiocytosis.
Wajda N; Zhu Z; Jandarov R; Dilling DF; Gupta N
Respirology; 2020 Jun; 25(6):644-650. PubMed ID: 31407478
[TBL] [Abstract][Full Text] [Related]
35. Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.
Mourah S; How-Kit A; Meignin V; Gossot D; Lorillon G; Bugnet E; Mauger F; Lebbe C; Chevret S; Tost J; Tazi A
Eur Respir J; 2016 Jun; 47(6):1785-96. PubMed ID: 27076591
[TBL] [Abstract][Full Text] [Related]
36. Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease.
McClain K
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):395-399. PubMed ID: 33275721
[TBL] [Abstract][Full Text] [Related]
37. The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study.
Tazi A; de Margerie C; Naccache JM; Fry S; Dominique S; Jouneau S; Lorillon G; Bugnet E; Chiron R; Wallaert B; Valeyre D; Chevret S
Orphanet J Rare Dis; 2015 Mar; 10():30. PubMed ID: 25887097
[TBL] [Abstract][Full Text] [Related]
38. Pulmonary Langerhans' cell histiocytosis.
Vassallo R; Ryu JH
Clin Chest Med; 2004 Sep; 25(3):561-71, vii. PubMed ID: 15331192
[TBL] [Abstract][Full Text] [Related]
39. Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.
Tran G; Huynh TN; Paller AS
J Am Acad Dermatol; 2018 Mar; 78(3):579-590.e4. PubMed ID: 29107340
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
